You are here
Award Data
The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.
Download all SBIR.gov award data either with award abstracts (290MB)
or without award abstracts (65MB).
A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.
The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.
-
Enhancing cytarabine efficacy in leukemia through CDK inhibition
SBC: SENEX BIOTECHNOLOGY, INC. Topic: 102Acute myeloid leukemia AML is the most common acute leukemia in adults with new cases annually in the US A deoxycytidine nucleoside analog Cytarabine AraC is the principal chemotherapeutic agent used in AML AraC containing chemotherapeutic regimens induce complete remission in of newly diagnosed AML patients but a substantial minority of leukemias is intrinsically resistant t ...
SBIR Phase I 2017 Department of Health and Human ServicesNational Institutes of Health -
Novel injectable resiquimod formulation for treatment of metastatic cancers
SBC: Curebiotech, Inc. Topic: NCIPROJECT SUMMARY Malignant melanoma is one of the most aggressive types of skin cancer causing a large majority of skin cancer related deaths worldwide Recently there have been staggering breakthroughs with the advent of drugs that act on checkpoint inhibitors These are paradigm shifting immunotherapeutic agents not only for melanoma but for cancers in general because they harness the bodyan ...
SBIR Phase I 2017 Department of Health and Human ServicesNational Institutes of Health -
CRISPR Cas Systems Delivered by Targeted Nanoparticles to Eradicate Herpesvirus Pathogens
SBC: Theragnostic Technologies Inc. Topic: NIAIDAbstract Herpesviruses are chronic pathogens that infect for life there is no cure years since the discovery of the first tumor virus the herpesvirus Epstein Barr virus EBV there exist no specific antivirals for EBV during its latency phase and there are no vaccines The same holds true for most of the other eight human herpesviruses This proposal aims to develop novel tools to eradicat ...
SBIR Phase I 2017 Department of Health and Human ServicesNational Institutes of Health -
Developing specific rapid and cost effective immunoassays for Zika detection
SBC: MEDIOMICS, LLC Topic: RThis proposal aims to develop highly specific rapid and cost effective immunoassays to detect Zika virus ZIKV infection ZIKV is a single stranded RNA virus in the Flaviviridae family that is transmitted to humans through infected mosquitos blood transfusions and sexual contact As of June around Zika Virus disease cases have been estimated in Brazil alone Recently ZIKV has be ...
SBIR Phase I 2017 Department of Health and Human ServicesNational Institutes of Health -
A Nitric Oxide Polymer Platform for the Prevention and Treatment of Infected Wounds
SBC: IFYBER LLC Topic: NIAIDThis proposed SBIR research effort will lay the foundation for commercializing a new class of biomaterial for the prevention and treatment of infected skin wounds thereby enhancing patient health through improved patient outcome and reduced patient morbidity Specifically we will focus on evaluating and developing a biomaterial comprised of a nitric oxide NO releasing based on a commonly used ...
SBIR Phase I 2017 Department of Health and Human ServicesNational Institutes of Health -
Targeting the alternative pathway to treat age related macular degeneration
SBC: Serion, Inc Topic: NTargeting the alternative pathway of complement to treat age related macular degeneration Abstract Age related macular degeneration AMD is the leading cause of vision loss in the developed world in people over and is a priority research area for the National Eye Institute It is a progressive degenerative disease that causes loss of the central vision due to destruction of the part of the re ...
SBIR Phase I 2017 Department of Health and Human ServicesNational Institutes of Health -
The Preemie Pacer An Innovative Bottle to Promote Safe and Efficient Oral Feeding in Preterm Infants
SBC: PREEMIE-PACER LLC Topic: NICHDPROJECT SUMMARY ABSTRACT There are infants born preterm each year in the United States alone Preterm infants often necessitate care in the neonatal intensive care unit One of the final milestones to be achieved in order to be discharged from the neonatal intensive care unit is oral feeding Oral feeding can be a challenge for infants born preterm as they do not have the maturity that all ...
SBIR Phase I 2017 Department of Health and Human ServicesNational Institutes of Health -
Fluorescent reporters for real time single cell Pol III transcription measurement
SBC: LUCERNA INC Topic: 400SUMMARY RNA polymerase III Pol III is increasingly recognized as an important drug target and a rapidly developing area of academic research Pol III is responsible for generating RNAs that are critical for cell growth such as tRNAs certain rRNAs and various noncoding RNAs involved in processes such as mRNA splicing These RNAs are required for cell growth proliferation and differentiation ...
SBIR Phase I 2017 Department of Health and Human ServicesNational Institutes of Health -
A phosphopeptide multiplex PRM mass spectroscopic biomarker assay for PAH
SBC: Pulmokine, Inc. Topic: NHLBIThe purpose of this phase SBIR grant is to develop a quantitative phosphopeptide biomarker assay for pulmonary arterial hypertension PAH The commercial product will consist of a kit of stable isotopically labeled internal standards of a selected set of phosphopeptides either up or down regulated in PAH The set of stable isotopically labeled peptides will be used in a parallel reaction monito ...
SBIR Phase I 2017 Department of Health and Human ServicesNational Institutes of Health -
A Phase 2 clinical trial of topical uracil for the prevention of capecitabine induced hand-foot syndrome
SBC: NANOMETICS LLC Topic: 102Problem to be SolvedCapecitabine is a widely prescribed and orally available prodrug of the chemotherapeutic agentfluorouracilFUThe principle dose schedule limiting toxicity associated with its use is Hand Foot syndromeHFSand occurs inof patients receiving capecitabineHFS manifests in the hands and feet of patientsand rapidly progresses to painful peelingblisteringand bleeding that commonly requir ...
SBIR Phase II 2017 Department of Health and Human ServicesNational Institutes of Health